Lead Product(s) : Rislenemdaz
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cerecor
Deal Size : $22.1 million
Deal Type : Acquisition
Cerecor and Aevi Genomic Medicine Complete Merger
Details : Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Rislenemdaz
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cerecor
Deal Size : $22.1 million
Deal Type : Acquisition
Lead Product(s) : Rislenemdaz
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Intermittent Doses of CERC-301 in MDD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2015
Lead Product(s) : Rislenemdaz
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rislenemdaz
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2013
Lead Product(s) : Rislenemdaz
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable